SCHEMBL191022

SCHEMBL191022

CCOC(=O)c1ccc(Cl)c(Oc2ccnc(Nc3nc(C)cs3)c2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 7/20 0.44
GRM5 P41594 2/20 0.43
TRPV4 Q9HBA0 2/20 0.42
SCD O00767 1/20 0.42
LMNA P02545 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MAPT P10636 2/20 0.39
MAPK1 P28482 2/20 0.39
ALDH1A1 P00352 2/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HSP90AA1 P07900 1/20 0.39
SMARCA2 P51531 1/20 0.38
SMARCA4 P51532 1/20 0.38
GAA P10253 1/20 0.38
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
CASP3 P42574 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL191747 0.92 GRM5 (0.45) GCKGRM5TRPV4SCDMAPT
SCHEMBL190404 0.91 GCK (0.46) GCKGRM5TRPV4LMNANPSR1
SCHEMBL190589 0.90 GCK (0.46) GCKGRM5TRPV4LMNANPSR1
SCHEMBL12305664 0.89 GAA (0.48) GCKGRM5TRPV4SCDRAB9A
Hydrochloric Acid SCHEMBL190606 0.88 GAA (0.47) GCKGRM5TRPV4SCDRAB9A
SCHEMBL190583 0.83 TRPV4 (0.48) GCKTRPV4MAPTMAPK1ALDH1A1
SCHEMBL2740569 0.83 GRM5 (0.41) GCKGRM5SCDALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL192190 0.82 GRM5 (0.41) GCKGRM5SCDALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL190882 0.82 GRM5 (0.41) GCKGRM5SCDALDH1A1SMN1; SMN2
SCHEMBL191157 0.82 TRPV4 (0.42) TRPV4SCDLMNAMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1986645-B1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC (US) 2012-01-04 EP disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
EP-1986645-A1 GLUCOKINASE ACTIVATORS Array Biopharma, Inc. (US) 2008-11-05 EP disclosed
WO-2007089512-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247526-A1 GLUCOKINASE ACTIVATORS GCKR, GCK, GALK1 GCK 2/4885GRM5 1123/4885TRPV4 4775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.